CN1211107C - Mixture for improving blood circulation - Google Patents
Mixture for improving blood circulation Download PDFInfo
- Publication number
- CN1211107C CN1211107C CN 02133547 CN02133547A CN1211107C CN 1211107 C CN1211107 C CN 1211107C CN 02133547 CN02133547 CN 02133547 CN 02133547 A CN02133547 A CN 02133547A CN 1211107 C CN1211107 C CN 1211107C
- Authority
- CN
- China
- Prior art keywords
- present
- group
- parts
- mixture
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a composition for improving blood circulation, which can be a medicine or a health-care product. The present invention is prepared from the following raw material components of the shares by weight: 0.1 to 500 of ginkgo leaf, 0.1 to 500 of haw and 0.1 to 500 of garlic. The ginkgo leaves and the haws of the proportion are made into water or ethanol extract, the garlic is made into garlic oil, and the three kinds of extract are mixed. The present invention can regulate blood fat, inhibit cerebral thrombosis and arteriosclerosis, resist senescence and improve memory. The present invention is convenient to take, and is easily accepted by users.
Description
Technical field
The present invention relates to the sanguimotor mixture of a kind of improvement, is health product or the Chinese patent medicine that raw material is made to comprise Folium Ginkgo, Fructus Crataegi, Bulbus Allii specifically, the invention still further relates to the preparation method of this chemical compound.
Technical background:
The disease of blood circulation aspect is the common disease that influences human health.Symptoms such as the patient shows as hyperlipidemia, hyperglycemia, cerebral thrombosis, arteriosclerosis, has a lapse of memory, insomnia, anemia, fatiguability, osteoporosis, anoxia.
At present existing with any two kinds in Folium Ginkgo, Fructus Crataegi, the Bulbus Allii be raw material, add the mixture that other material is made, to all kinds of cardiovascular disease, be good for the stomach, strengthen body immunity, memory has certain curative effect.
The content of invention:
The purpose of this invention is to provide a kind of easy raising immunity, blood sugar lowering, blood pressure, slow down aging, improvement memory, improve vision, improve sleep, resisting fatigue, anoxia enduring, radioprotective, improve osteoporosis, improve nutritional anemia, anti-chemical liver damage, improve gastrointestinal function and improve sanguimotor mixture, this mixture can be medicine or health product.
The present invention is achieved in that
The present invention improves sanguimotor mixture, this mixture comprises that the raw material of following weight portion makes: Folium Ginkgo 0.1-500, Fructus Crataegi 0.1-500, Bulbus Allii 0.1-500, the Folium Ginkgo and the Fructus Crataegi of said ratio are made water or alcohol extract, and Bulbus Allii is made Oleum Bulbus Allii, three kinds of extracts are mixed.
Its raw material of the present invention also contains Semen Ziziphi Spinosae or the Bulbus Lilii or the Radix Rhodiolae of 0.1-500 weight portion.
The dosage form of this mixture of the present invention is an oral formulations.
Peroral dosage form of the present invention is tablet, capsule, oral liquid, soft capsule, powder.
Contain Folium Ginkgo extract 3.0g in the every 100g mixture of the present invention, Fructus Crataegi extract 5.0g, Oleum Bulbus Allii 1.0g, Semen Ziziphi Spinosae extract 10.0g and Bulbus Lilii extract 8.0g.
Contain Folium Ginkgo extract 4.0g in the every 100g mixture of the present invention, Fructus Crataegi extract 4.0g, Oleum Bulbus Allii 1.0g, Radix Rhodiolae extract 20.0g.
The present invention is the mixture of main component with the extract of Folium Ginkgo, Fructus Crataegi, Bulbus Allii, and the blood circulation of improvement is arranged, and blood lipid regulation suppresses cerebral thrombosis and arteriosclerotic effect.On the basis of main component, add other materials; the health product of forming; Chinese patent medicine is except that having above-mentioned effect; also can increase other the function that cures mainly, as have immunomodulating; blood sugar regulation; improve memory effect; improve the vision effect; promote lead-eliminating effect; effects of clearing and nourishing throat; the blood pressure regulation effect; improve the sleep effect; promote Lactation; antimutagenic effect; antifatigue effect; resisting oxygen lack; radiation resistance; antiobesity action; promote the growth promoter effect; improve the osteoporosis effect; improve the nutritional anemia effect; chemical liver injury there is auxiliary protection function; beautification function; improve gastrointestinal function.Safe without toxic side effect of the present invention, raw material sources are abundant, and inexpensive, processing technology is simple, can be made into various dosage forms, taking convenience.
The specific embodiment:
Embodiment 1:
Proportion of raw materials (weight portion) is as follows:
Folium Ginkgo 3.0
Fructus Crataegi 5.0
Bulbus Allii 1.0
Semen Ziziphi Spinosae 10.0
Bulbus Lilii 8.0
(1) preparation method of Folium Ginkgo extract, Fructus Crataegi extract:
Folium Ginkgo decocting 2 times filters, and collecting decoction concentrates, and in 70-80 ℃ of drying, makes powder.The same Folium Ginkgo extract of the preparation method of Fructus Crataegi extract.
(2) preparation method of Oleum Bulbus Allii
The Bulbus Allii vapor distillation gets Oleum Bulbus Allii.
(3) preparation of patent medicine
With Folium Ginkgo extract, Fructus Crataegi extract, Oleum Bulbus Allii mix homogeneously, splash in the medium, cooling promptly gets soft capsule.
This capsular function is for improving sleep, blood lipid regulation.
Clinical experiment is as follows:
One, improves the sleep effect
1, material and method
1.1 sample: the capsule that mixture of the present invention is made is provided by Chengdu Guojia Inst. of Medicines, lot number: 20020128.Sample (capsule 's content) outward appearance is the brown oily liquids, and the human body recommended intake is 1.5g/ people/day.Use edible blend oil dilution back to irritate stomach.
1.2 experimental animal: three grades of female Mus of Kunming kind, body weight 18-25g provides the (quality certification number: SCXK11-00-0010) by Nat'l Pharmaceutical ﹠ Biological Products Control Institute's Experimental Animal Center.Raising condition: SPF level Animal House.
1.3 dosage is selected: 250mg/kg.bw, 750mg/kg.bw (be equivalent to respectively human body recommended intake 1.0g/ people/day 10,20,30 times).
1.4 experimental technique:
1.4.1 prolong the inductive mouse sleep time test of pentobarbital sodium: adult mice is divided into 4 groups (promptly protecting three dosage groups of blood caring soft capsule and negative control group) at random.Protect blood caring soft capsule content aqueous solution and irritate stomach once every day by 2% volume, continuous 4 weeks.Negative control group is irritated edible blend oil, and last is irritated stomach and given each treated animal lumbar injection pentobarbital sodium 60mg/kg.bw after 30 minutes, observes and write down deep sleep (promptly the losing righting reflex) persistent period of injection back animal.Calculate the average length of one's sleep of each treated animal respectively.
1.4.2 pentobarbital sodium sub-threshold dose hypnosis test: grouping, irritate stomach method and time all with
2 results
1.4.1。Last was irritated stomach after 30 minutes, pressed 35mg/kg.bw dosage and gave each treated animal lumbar injection pentobarbital sodium normal saline solution, observed the sleeping number of animals (surpassing 2 minutes with righting reflex loss serves as to judge sleeping standard) of injecting in back 30 minutes.Calculate the sleep incidence rate of each treated animal respectively.
1.4.3 barbital sodium inducing mouse sleep latent time test: grouping, filling stomach method and all same 1.4.1 of time.Last is irritated stomach and is given each treated animal lumbar injection barbital sodium 240mg/kg.bw after 30 minutes, observes and write down the time for falling asleep of injection back animal.Calculate the average sleep latent time (being time for falling asleep-injection barbital sodium time) of each treated animal respectively.
1.5 experimental data statistics: the X 2 test of sleep incidence rate, the length of one's sleep, sleep latent time and body weight are done the comparison (the heterogeneity of variance person uses rank test) of group difference with variance analysis.
2.1 capsule of the present invention is to the influence of mice body weight: see Table 1.The good board of state protects each dosage treated animal average weight of blood caring soft capsule and matched group does not relatively have significant difference (P＞0.05) when ANOVA showed significant test mid-term and off-test, shows that this inspection product have no adverse effects to the mice growth promoter.
Table 1 soft capsule of the present invention is to the influence of mice body weight
The initial body weight of number of animals body weight in mid-term finishes body weight
Group
(only) (g) (g) (g)
Contrast 41 22.26 ± 1.55 28.27 ± 2.04 30.76 ± 2.00
250mg/kg.bw 41 22.29±1.40 27.29±2.08 30.22±2.46
500mg/kg.bw 41 22.27±1.47 27.66±2.36 30.02±2.59
750mg/kg.bw 41 22.32±1.42 27.59±2.26 30.17±2.33
2.2 prolong the inductive mouse sleep time test of pentobarbital sodium: see Table 2.All have in various degree than matched group the average length of one's sleep of protecting each dosage group mice of blood caring soft capsule to prolong, the average length of one's sleep of 250mg/kg.bw group mice and matched group be significant prolongation (P＜0.01) relatively.Be that this inspection product have the prolongation effect to the inductive mouse sleep time of high dose pentobarbital sodium.
Table 2 soft capsule of the present invention is to the influence of the inductive mouse sleep time of pentobarbital sodium
The dosage pentobarbital sodium dosage number of animals length of one's sleep (branch)
P value *
(mg/kg.bw) (mg/kg.bw) (only) (X ± S)
0 60 13 67.77±20.03
250 60 13 93.62±27.63 ＜0.01
500 60 13 77.08±18.83 ＞0.05
750 60 13 80.23±18.38 ＞0.05
* compare with negative control group
2.3 pentobarbital sodium sub-threshold dose hypnosis examination
2.4 test: see Table 3.Sleep incidence rate of each dosage group mice of soft capsule of the present invention and matched group relatively do not have significant difference (P＞0.05), i.e. this inspection product do not have obvious influence to the inductive mice sleep incidence rate of pentobarbital sodium.
Table 3 soft capsule of the present invention is to the influence of sub-threshold dose pentobarbital sodium inducing mouse sleep incidence rate
Dosage
The sleeping number of animals sleep of pentobarbital sodium dosage number of animals takes place
(mg/kg.bw P value *
(mg/kg.bw) (only) (only) rate (%)
)\
0 35 15 4 26.67
250 35 15 3 20.00 ＞0.05
500 35 15 5 33.33 ＞0.05
750 35 15 4 26.67 ＞0.05
Compare with negative control group
2.4 barbital sodium inducing mouse sleep latent time test: see Table 4.More all there were significant differences (P＜0.01) for average sleep latent time of each dosage group mice of soft capsule of the present invention and matched group, i.e. this inspection product have the shortening effect to the inductive mice sleep latent time of barbital sodium.
Table 4 soft capsule of the present invention is to the influence of the inductive mice sleep latent time of barbital sodium
Dosage barbital sodium dosage number of animals sleep latent time (branch)
P value *
(mg/kg.bw) (mg/kg.bw) (only) (X ± S)
0 240 13 31.69±4.35
250 240 13 25.08±6.58 ＜0.01
500 240 13 26.16±6.83 ＜0.01
750 240 13 28.38±3.07 ＜0.01
Compare with negative control group
1 brief summary
Soft capsule of the present invention improves sleep effect animal test results and shows that this inspection product have no adverse effects to the mice growth promoter; In prolonging the inductive mouse sleep time test of pentobarbital sodium, significantly be longer than matched group the average length of one's sleep of protecting blood caring soft capsule 250mg/kg.bw dosage group mice; In the test of barbital sodium inducing mouse sleep latent time, the average sleep latent time that protects each dosage group mice of blood caring soft capsule significantly is shorter than matched group (P＜0.01).By evaluation criterion, this inspection product (soft capsule of the present invention) have the sleep of improvement effect.
Two, blood lipid regulation effect
1 material and method
1.1 sample: soft capsule of the present invention is provided by Chengdu Guojia Inst. of Medicines.The human body recommended dose is 1500mg/ people/day.Capsule 's content is brown suspendible grease.
1.2 laboratory animal: 56 of SD rats, body weight 155-200g, male and female half and half provide (No. the 24101113rd, the moving word of doctor) by Sichuan University's Experimental Animal Center.
1.3 feedstuff: 1) normal feedstuff: Sichuan University's Experimental Animal Center provides.2) high lipid food (%): normal feedstuff 93.8, Adeps Sus domestica 5, cholesterol 1 (CP level, imported from Holland packing), cholate 0.2.
1.4 key instrument and reagent: ISP-M type semi-automatic biochemical analyzer (Holland), Australian Trace company clinical biochemical reagent.
1.5 experimental technique: rat uses normal feedstuff adaptability feed after three days, get tail hematometry basis TC, TG and HDL-C level, according to the TC level, be divided into following four groups by the random packet principle: 125mg/kg group, 250mg/kg group, 500mg/kg group (be equivalent to respectively human intaking amount 25mg/kg/ people/day 5,10,20 times) and high fat matched group, 12 every group.The experimental group animal is irritated stomach with the blood caring soft capsule content that protects of corresponding dosage, and high fat matched group is irritated stomach with Clean products.Tested the 30th day, and got hematometry TC, TG and HDL-C from rat femoral.
6 experimental datas statistics: other significance test of difference in means (t inspection)
2 results
2.1 the present invention sees Table 1 than the influence of capsule to rat body weight.
Table 1 soft capsule of the present invention is to the influence of rat body weight
Body weight (g)
Number of animals
Group
Weightening finish (g)
(only)
The initial end
High fat matched group 12 175.42 ± 10.97 274.17 ± 17.69 98.75 ± 15.97
125mg/kg organizes 12 172.08 ± 10.33 269.58 ± 17.51 96.97 ± 13.20
250mg/kg organizes 12 173.75 ± 14.32 266.67 ± 20.04 92.92 ± 11.77
500mg/kg organizes 12 182.08 ± 11.37 281.25 ± 13.16 99.17 ± 12.94
By table 1 as seen, body weight of each experimental group rat and weightening finish are compared there was no significant difference with high fat matched group.
Soft capsule of the present invention is to the influence of rat fat: see Table 2.
Table 2 soft capsule of the present invention is to the influence of Serum TC, TG, HDL-C
TC mg/dl TG mg/dl
Number of animals
Group
(only)
After testing before the preceding test of the test back test
High fat matched group 12 91.63 ± 12.25 126.49 ± 19.23 67.04 ± 22.52 132.56 ± 21.28
125mg/kg organizes 12 94.53 ± 14.96 128.16 ± 24.24 66.14 ± 22.77 130.13 ± 34.97
250mg/kg organizes 12 94.23 ± 13.68 108.40 ± 18.86* 66.43 ± 24.03 108.88 ± 16.68
500mg/kg organizes 12 95.73 ± 10.48 103.14 ± 13.08** 66.91 ± 15.00 96.43 ± 10.45*
Compare with high fat matched group,
*P＜0.05,
*P＜0.01.
By table 2 as seen, the TC and the TG level of test back 250mg/kg and 500mg/kg group significantly are lower than high fat matched group (P＜0.05, P＜0.01).
3 brief summaries
Soft capsule of the present invention has blood lipid regulation (triglyceride reducing and cholesterol) effect under the zoopery condition.
Embodiment 2:
Proportion of raw materials is as follows: weight portion
Folium Ginkgo 4.0
Fructus Crataegi 4.0
Oleum Bulbus Allii 1.0
Radix Rhodiolae 20.0
(1) preparation method of Folium Ginkgo extract, Fructus Crataegi extract:
Folium Ginkgo decocting 2 times filters, and collecting decoction concentrates, and in 70-80 ℃ of drying, makes powder.The same Folium Ginkgo extract of the preparation method of Fructus Crataegi extract.
The same Folium Ginkgo extract of the preparation method of Radix Rhodiolae extract.
(2) preparation method of Oleum Bulbus Allii
The Bulbus Allii vapor distillation gets Oleum Bulbus Allii.
(3) preparation of patent medicine
With Folium Ginkgo extract, Fructus Crataegi extract, Oleum Bulbus Allii mix homogeneously, splash in the medium cooling and promptly get soft capsule.
This capsular function is a resisting fatigue, blood lipid regulation.
Pharmacological evaluation is as follows:
One, antifatigue effect
1 material and method
1.1 sample: soft capsule of the present invention (content) is brown oil, is provided by Chengdu Guojia Inst. of Medicines, is configured to desired concn with salad oil.
1.2 laboratory animal and raising: the one-level Male Kunming strain mice provides (the animal quality certification number: No. the 24101102nd, the moving word of doctor) by Sichuan Province's medical courses in general institute animal center.
1.3 dosage is selected: test group is established basic, normal, high three dosage by 10 times, 20 times, 30 times of the human body recommended amounts (500m * 3/ people/sky) of product (promptly 0.25,0.50,0.75g/kg.bw).
1.4 key instrument and reagent: Dutch IST-I type semi-automatic biochemical analyzer, SBA-bio-sensing analyser, Vis7200 spectrophotometer, Syrup-homogenizing instrument, centrifuge, electronic balance.
1.5 test method: be divided into a negative group and three test group at random by the body weight size, test group is given sample (irritating body of stomach long-pending is 2%) to irritate the stomach mode, and negative control group gives distilled water, once a day, and continuous 30 days.Measure every index after 30 days respectively.
1.5.1 swimming with a load attached to the body test: after last is irritated stomach 30 minutes, with the load sheet lead of 5% body weight of mice, put into swimming in the swimming case (depth of water 30cm, 25 ± 0.5 ℃ of water temperatures), the record mice is the mice swimming time from swimming to the death time.
1.5.2 pole-jump test: after last is irritated stomach 30 minutes, mice is put on the lucite of pole-climbing frame, makes its muscle be in the static(al) tense situation, the record mice because of muscle fatigue from time that bar falls, triplicate, the continuous three times time of accumulative total is pole-climbing time (second).
1.5.3 blood urea nitrogen, hepatic glycogen are measured: irritated behind the stomach 30 minutes respectively at last, mice is put into swimming case (depth of water 30cm, 30 ± 0.5 ℃ of water temperatures) swimming is 90 minutes in, gets eyeball hematometry serum urea nitrogen content (diacetyl-oxime method), gets liver and measures hepatic glycogen content (anthrone method).
1.5.4 lactic acid is measured; Last was irritated behind the stomach 30 minutes, get eyeball and measure lactic acid content, the mice sheet lead of 4% body weight (the Mus root of the tail portion load) is put into the swimming case) depth of water 30cm, 30 ± 0.5 ℃ of water temperatures) in swimming 10 minutes, respectively at after the swimming at once, swimming got blood in back 30 minutes and measures lactic acid content again.
1.6 the experimental data statistics: experimental data is carried out statistical analysis with the SPS9.0 statistical software.
2 results
2.1 soft capsule of the present invention is to the influence of mice body weight
Table 1 shows, three dosage group mice initial weight, middle weight, heavy and negative control group relatively there are no significant difference (P＞0.05) eventually.
Table 1 soft capsule of the present invention is to the influence of mice body weight
Final period in mid-term dosage initial stage
(g/kg.bw
Animal (only) body weight (g) animal (only) body weight animal (only) body weight
)\
(g) (g)
Negative control-60 20.37 ± 1.81 60 31.37 ± 3.30 58 37.83 ± 4.03
Low 0.25 60 20.37 ± 1.82 59 31.61 ± 3.17 55 37.87 ± 3.89
In 0.50 60 20.37 ± 1.80 59 31.63 ± 3.11 55 37.87 ± 3.57
High by 0.75 60 20.37 ± 1.81 60 30.83 ± 2.83 57 37.63 ± 3.49
2.2 soft capsule of the present invention is to the influence of mice swimming with a load attached to the body time
See Table 2, the high dose group mice swimming with a load attached to the body time is apparently higher than negative control group (P＜0.05); There are no significant (P＞0.05) for other dosage group mice swimming with a load attached to the body times and negative control group comparing difference.
Table 2 soft capsule of the present invention is to the influence of mice swimming with a load attached to the body time
| Dosage (g/kg.bw) | Number of animals (only) | Swimming time (second) | P value * |
| Negative control- | 12 | 208.0±49.4 | |
| Low 0.25 | 12 | 284.9±107.0 | ＞0.05 |
| In 0.50 | 12 | 266.8±79.11 | ＞0.05 |
| High by 0.75 | 11 | 322.2±109.2 | ＜0.05 |
* compare with negative control group
2.3 soft capsule of the present invention is to the influence of mice pole-climbing time
See Table 3, the middle and high dosage group mice pole-climbing time obviously is longer than negative control group (P＜0.05, P＜0.01).
Table 3 soft capsule of the present invention is to the influence of mice pole-climbing time
| Dosage (g/kg.bw) | Number of animals (only) | The pole-climbing time (second) | P value * |
| Negative control- | 12 | 72.00±35.01 | |
| Low 0.25 | 12 | 93.42±39.11 | ＞0.05 |
| In 0.50 | 12 | 121.83±49.99 | ＜0.05 |
| High by 0.75 | 12 | 138.50±66.46 | ＜0.05 |
* compare with negative control group
2.4 soft capsule of the present invention to mouse movement after the influence of serum urea nitrogen
Serum urea nitrogen content and negative control group comparing difference there are no significant difference (P＞0.05) sees Table 4 behind each dosage group mouse movement.
Table 4 soft capsule of the present invention to mouse movement after the influence of serum urea nitrogen content
| Dosage (g/kg.bw) | Number of animals (only) | Serum urea nitrogen content (mmol/L) | P value * |
| Negative control- | 12 | 7.86±1.16 | |
| Low 0.25 | 12 | 8.48±1.12 | ＞0.05 |
| In 0.50 | 12 | 8.59±1.01 | ＞0.05 |
| High by 0.75 | 12 | 7.87±1.62 | ＞0.01 |
* compare with negative control group
2.5 soft capsule of the present invention to mouse movement after the influence of hepatic glycogen content
See Table 5, hepatic glycogen content is apparently higher than negative control group (P＜0.05) behind the high dose group mouse movement; Hepatic glycogen content and negative control group comparing difference do not have significance (P＞0.05) behind other dosage group mouse movements.
Table 5 soft capsule of the present invention to mouse movement after the influence of hepatic glycogen content
| Dosage (g/kg.bw) | Number of animals (only) | Hepatic glycogen content (mg/100g liver) | P value * |
| Negative control- | 12 | 1082.1±593.9 | |
| Low 0.25 | 12 | 1063.2±644.8 | ＞0.05 |
| In 0.50 | 12 | 1166.4±640.4 | ＞0.05 |
| High by 0.75 | 12 | 1755.8/±468.5 | ＜0.05 |
* compare with negative control group
2.6 soft capsule of the present invention is to the table 6 that influences of mouse movement bleeding from anus lactate level, 7 show, compare with negative control group, and the lactic acid range of decrease obviously increases (P＜0.05) behind the high dose group mouse movement.Lactic acid increasing degree and lactic acid range of decrease there was no significant difference (P＞0.05) behind other dosage group mouse movements.
Table 6 soft capsule of the present invention is to the influence of mouse movement bleeding from anus lactic acid rising amplitude
| Dosage (g/kg.bw) | Number of animals (only) | Hepatic glycogen content (mmol/L) | P value * | ||
| Before the motion (A) | Motion back 0min (B) | Difference (B-A) | |||
| Negative control- | 12 | 2.04±0.86 | 7.04±1.57 | 5.00±1.83 | |
| Low 0.25 | 12 | 3.82±1.92 | 7.00±1.61 | 3.18±2.74 | ＞0.05 |
| In 0.50 | 12 | 3.86±1.33 | 7.23±1.27 | 3.56±1.26 | ＞0.05 |
| High by 0.75 | 11 | 3.63±1.98 | 7.64±2.46 | 4.00±1.36 | ＞0.05 |
* difference (B-A) compares with negative control group
Table 7 soft capsule of the present invention is eliminated the influence of amplitude to mouse movement bleeding from anus lactic acid
| Dosage (g/kg.bw) | Number of animals (only) | Hepatic glycogen content (mmol/L) | P value * | ||
| Motion back 0min (B) | Motion back 30min (C) | Difference (B-C) | |||
| Negative control- | 12 | 7.04±1.57 | 3.91±2.30 | 3.18±1.60 | |
| Low 0.25 | 12 | 7.00±1.61 | 2.83±1.36 | 4.17±1.80 | ＞0.05 |
| In 0.50 | 12 | 7.23±1.27 | 3.03±0.84 | 4.20±0.96 | ＞0.05 |
| High by 0.75 | 11 | 7.64±2.46 | 2.8 3±1.42 | 4.97±2.04 | ＜0.05 |
3 brief summaries
Press 10 times, 20 times, 30 times of human body recommended dose (500m * 3/ people/sky) (promptly 0.25,0.50,0.75g/kg.bw) respectively, per os gives mice soft capsule of the present invention (content) 30 days, and the result shows: the middle and high dosage group mice pole-climbing time is significantly higher than negative control group (P＜0.05, P＜0.01); Compare with negative control group, high dose group mice swimming with a load attached to the body time, motion back hepatic glycogen content and blood lactic acid reduce amplitude and all significantly increase (P＜0.05); All the other each groups compare there was no significant difference (＞0.05) with negative control group.By evaluation criterion, this inspection product have antifatigue effect.
Two, blood lipid regulation effect
1 material and method
1.1 sample: capsule of the present invention is provided by Chengdu Guojia Inst. of Medicines.The human body recommended dose is 1500mg/ people/day.The capsule 's content outward appearance is the transparent grease of sepia.
1.2 laboratory animal: 48 of SD rats, body weight 145-200g, male and female half and half provide (No. the 24101113rd, the moving word of doctor) by Sichuan University's Experimental Animal Center.
1.3 feedstuff: 1) normal feedstuff: Sichuan University's Experimental Animal Center provides.2) high lipid food (%): normal feedstuff 93.8, Adeps Sus domestica 5, cholesterol 1 (CP level, imported from Holland packing), cholate 0.2.
1.4 key instrument and reagent: ISP-M type semi-automatic biochemical analyzer (Holland), Australian Trace company clinical biochemical reagent.
1.5 experimental technique: rat uses normal feedstuff adaptability feed after three days, get tail hematometry basis TC, TG and HDL-C level, according to the TC level, be divided into following four groups by the random packet principle: 125mg/kg group, 250mg/kg group, 500mg/kg group (be equivalent to respectively human intaking amount 25mg/kg/ people/day 5,10,20 times) and high fat matched group, 12 every group.Three experimental group animals are irritated stomach with the soft capsule content of the present invention of corresponding dosage, and high fat matched group is irritated stomach with Clean products.Tested the 30th day, and got hematometry TC, TG and HDL-C from rat femoral.
1.6 experimental data statistics: t check.
2 results
2.1 soft capsule of the present invention sees Table 1 to the influence of rat body weight.
Table 1 soft capsule of the present invention is to the influence of rat body weight
Body weight (g)
Number of animals
Group
Weightening finish (g)
(only)
The initial end
175.77± 265.00±
High fat matched group 12 98.00 ± 20.51
13.52 125.82
125mg/kg organizes 12 176.54 ± 9.44 254.17 ± 29.91 79.58 ± 32.37
176.15±
250mg/kg organizes 12 252.69 ± 24.55 76.54 ± 20.35
10.64
172.00±
500mg/kg organizes 12 246.67 ± 20.04 75.42 ± 20.17
13.86
By table 1 as seen, body weight of each experimental group rat and weightening finish are compared there was no significant difference with high fat matched group.
2.2 soft capsule of the present invention is to the influence of rat fat: see Table 2.
The rich invention soft capsule of table 2 is to the influence of Serum TC, TG, HDL-C
TC mg/dl TG mg/dl
Number of animals
Group
(only)
After testing before the preceding test of the test back test
High fat matched group 12 67.57 ± 9.05 112.84 ± 17.33 62.06 ± 12.49 124.11 ± 38.63
125mg/kg organizes 12 65.98 ± 8.50 97.50 ± 12.13* 63.65 ± 14.62 111.47 ± 28.38
250mg/kg organizes 12 72.63 ± 13.93 99.70 ± 21.86 62.49 ± 11.91 91.28 ± 33.50*
500mg/kg organizes 12 71.66 ± 13.61 101.83 ± 13.69 64.15 ± 17.36 73.63 ± 18.75**
Compare with high fat matched group,
*P＜0.05,
*P＜0.01.
By table 2 as seen, the TG level of TC, the 250mg/kg of test back 125mg/kg group and 500mg/kg group significantly is lower than high fat matched group (P＜0.05, P＜0.01).
3 brief summaries
The present invention's capsule that feels like jelly has blood lipid regulation (triglyceride reducing and cholesterol) effect under the zoopery condition.
Claims (6)
1, the sanguimotor mixture of a kind of improvement, it is characterized in that this mixture comprises that the raw material of following weight portion makes: Folium Ginkgo 0.1-500, Fructus Crataegi 0.1-500, Bulbus Allii 0.1-500, the Folium Ginkgo and the Fructus Crataegi of said ratio are made water or alcohol extract, Bulbus Allii is made Oleum Bulbus Allii, three kinds of extracts are mixed.
2, mixture according to claim 1 is characterized in that its raw material also contains Semen Ziziphi Spinosae or the Bulbus Lilii or the Radix Rhodiolae of 0.1-500 weight portion.
3, mixture according to claim 2, the dosage form that it is characterized in that this mixture is an oral formulations.
4, mixture according to claim 3 is characterized in that peroral dosage form is tablet, capsule, oral liquid, soft capsule, powder.
5, mixture according to claim 1 and 2 is characterized in that containing 3.0 parts of Folium Ginkgo extracts on per 100 weight portion mixture substantially, 5.0 parts of Fructus Crataegi extracts, 1.0 parts of Oleum Bulbus Alliis, 8.0 parts of 10.0 parts of Semen Ziziphi Spinosae extracts and Bulbus Lilii extracts.
6, want 1 or 2 described mixture according to right, it is characterized in that containing 4.0 parts of Folium Ginkgo extracts on per 100 weight portion mixture substantially, 4.0 parts of Fructus Crataegi extracts, 1.0 parts of Oleum Bulbus Alliis, 20.0 parts of Radix Rhodiolae extracts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02133547 CN1211107C (en) | 2002-07-30 | 2002-07-30 | Mixture for improving blood circulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02133547 CN1211107C (en) | 2002-07-30 | 2002-07-30 | Mixture for improving blood circulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1390594A CN1390594A (en) | 2003-01-15 |
| CN1211107C true CN1211107C (en) | 2005-07-20 |
Family
ID=4747262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02133547 Expired - Fee Related CN1211107C (en) | 2002-07-30 | 2002-07-30 | Mixture for improving blood circulation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1211107C (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100394930C (en) * | 2005-10-19 | 2008-06-18 | 暨南大学 | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product |
| CN1907446B (en) * | 2006-08-15 | 2012-04-25 | 李滋星 | Health care combined pills |
| CN101317615B (en) * | 2007-06-08 | 2011-05-25 | 上海中医药大学 | Silver-thorn tea beverage and preparation method thereof |
| CN102114202B (en) * | 2009-12-31 | 2012-02-29 | 福建归真堂药业股份有限公司 | Liver-protecting composition and preparation method thereof |
| CN101797331B (en) * | 2010-04-06 | 2014-10-15 | 陕西中美天顺药业有限公司 | Traditional Chinese medicine formula of application for preventing ophthalmic diseases |
| CN101940297B (en) * | 2010-08-08 | 2014-09-10 | 程振雷 | Food-therapy nutrient product capable of strengthening body, stimulating appetite and nourishing stomach |
| CN102018822B (en) * | 2010-12-29 | 2011-11-23 | 攀枝花学院 | Compound brewing-resistance glossy ganoderma tea and preparation method and application thereof |
| CN102178760B (en) * | 2011-04-11 | 2012-07-04 | 海南京润珍珠生物技术股份有限公司 | Lipid regulating pearl capsule |
| CN102178911B (en) * | 2011-04-21 | 2012-08-29 | 北京身心康国际中医研究院 | Chinese medicine preparation used for dispelling wind and eliminating dampness, dredging collaterals and stopping pains for people with deficiency of yang and phlegm dampness constitution, and preparation method and application of preparation |
| CN102265951B (en) * | 2011-08-10 | 2014-11-05 | 河南茗轩食品科技有限公司 | Tea for homolysis and lipopenicillinase and preparation method thereof |
| CN102342448B (en) * | 2011-08-29 | 2013-05-08 | 马建民 | Health-care food for reducing blood fat and serum cholesterase and preparation method thereof |
| CN102342562B (en) * | 2011-09-12 | 2013-03-06 | 湖南英氏营养食品有限公司 | Preparation method of infant solid beverage beneficial for sleeping and clearing heat |
| CN102366104B (en) * | 2011-10-29 | 2012-12-05 | 山西振东五和健康食品股份有限公司 | Nutritive food for tumor patients |
| CN102366102B (en) * | 2011-10-29 | 2012-12-05 | 山西振东五和健康食品股份有限公司 | Food suitable for tumor patients |
| CN102429223A (en) * | 2011-11-11 | 2012-05-02 | 完美（中国）有限公司 | Health care food with assistant blood fat reducing function and preparation method thereof |
| CN102552694B (en) * | 2012-02-15 | 2013-12-11 | 西南交通大学 | Medicinal preparation for treating upper gastrointestinal hemorrhage and preparation method thereof |
| CN102716338A (en) * | 2012-06-29 | 2012-10-10 | 遵义臻坤中草医药研究所 | Traditional Chinese medicine composition for activating human body dormancy stem cells and delaying senium |
| CN102784351B (en) * | 2012-08-30 | 2015-07-08 | 黄美钦 | Jujube kernel-poria cocos-oolong teabag and manufacture method thereof |
| CN103798754A (en) * | 2012-11-07 | 2014-05-21 | 苏州市洋海电子有限公司 | Traditional chinese medicine composition |
| CN103933488A (en) * | 2013-01-17 | 2014-07-23 | 赵明义 | Formula for treating cerebral thrombosis |
| CN104055098A (en) * | 2013-03-22 | 2014-09-24 | 张金余 | Dietotherapy composition for reducing blood lipid |
| CN103229866A (en) * | 2013-03-29 | 2013-08-07 | 薛朝贵 | Chicken liver powder-containing healthcare tea beverage and preparation method thereof |
| CN103251715B (en) * | 2013-05-10 | 2014-08-27 | 南京中医药大学 | Composition for regulating Th1/Th2 cell ratio and preparation method thereof |
| CN103463345A (en) * | 2013-08-27 | 2013-12-25 | 王国荣 | Chinese herbal preparation for treating cerebral thrombosis |
| CN103494731B (en) * | 2013-09-22 | 2015-06-17 | 章俊 | Shampoo |
| CN103463605A (en) * | 2013-09-25 | 2013-12-25 | 刘越泽 | Medicament for treating hypertension |
| CN103505710B (en) * | 2013-09-27 | 2015-06-17 | 张娟 | Health protection medicine for regulating blood fat and preparation method thereof |
| CN103565873B (en) * | 2013-10-12 | 2016-03-09 | 中国人民解放军兰州军区疾病预防控制中心 | A kind of compound preparation with anti-hypoxia stress function |
| CN103599482B (en) * | 2013-11-19 | 2016-04-13 | 太和县中医院 | A kind of Chinese medicine for the treatment of lochiorrhea |
| CN103566046A (en) * | 2013-11-25 | 2014-02-12 | 楚雄三平裕康商贸有限公司 | Traditional Chinese medicine composition containing maca, traditional Chinese medicine preparation, and preparation method of traditional Chinese medicine preparation |
| CN103610008A (en) * | 2013-11-25 | 2014-03-05 | 安徽强旺调味食品有限公司 | Liquid seasoning composition with effect of controlling hyperlipidemia and preparation method thereof |
| CN103656496B (en) * | 2013-11-26 | 2015-12-02 | 张雅静 | Rhizoma Sparganii Radix Curcumae electuary and preparation method thereof |
| CN103610835B (en) * | 2013-12-17 | 2015-07-15 | 刘凤阁 | Medicament for treating fundus hemorrhage |
| CN103830371B (en) * | 2014-03-02 | 2015-07-15 | 苑爱云 | Medicinal preparation for promoting cerebral micro-circulation |
| CN103908630A (en) * | 2014-03-16 | 2014-07-09 | 任瑞梅 | Pharmaceutical composition for treating nutritional iron-deficiency anemia |
| CN103989163B (en) * | 2014-04-30 | 2016-11-23 | 新时代健康产业（集团）有限公司 | A kind of blood stasis body constitution health food and preparation method thereof |
| CN104000267B (en) * | 2014-06-12 | 2015-08-05 | 北京美俏佳人生物科技有限公司 | A kind of anti-ageing healthcare oral liquid containing Chinese spun gold extract |
| CN104095088A (en) * | 2014-06-19 | 2014-10-15 | 赵玲 | Pu'er tea beverage containing brown rice and preparation method thereof |
| CN104095135A (en) * | 2014-07-17 | 2014-10-15 | 桐城市永锦建筑工程有限公司 | Health care tea |
| CN104127866B (en) * | 2014-08-02 | 2016-04-27 | 孙国真 | A kind of health product for relieving the effect of alcohol |
| CN104127865B (en) * | 2014-08-02 | 2016-04-27 | 孙国真 | For the health product relieved the effect of alcohol |
| CN104147387A (en) * | 2014-08-13 | 2014-11-19 | 高丽丽 | Traditional Chinese medicinal preparation for treating cerebral thrombosis |
| CN104256421A (en) * | 2014-09-25 | 2015-01-07 | 武汉一元堂生物科技有限公司 | Composition for reducing weight of female and improving gastroenteric function (relaxing bowel) and preparation method of composition |
| CN104256612B (en) * | 2014-10-11 | 2016-10-05 | 王�琦 | A kind of food improving blood stasis body constitution and preparation technology thereof |
| CN104491098A (en) * | 2015-01-19 | 2015-04-08 | 孙宁 | Instant donkey-hide gelatin product for patient with lung cancer and preparation method thereof |
| CN104666277A (en) * | 2015-01-31 | 2015-06-03 | 新疆欣予辰生物科技有限公司 | Preparation and application of mulberry compound microcapsule |
| CN105533753B (en) * | 2015-12-29 | 2018-03-30 | 徐州市铜山区生命科学研究院 | A kind of compound nutritional agent of medicine-food two-purpose preventing and treating microcirculation disorder |
| CN105749210A (en) * | 2016-03-04 | 2016-07-13 | 薛文婷 | Combined agent for gastric lavage in department of gastroenterology |
| CN105902803A (en) * | 2016-06-03 | 2016-08-31 | 广州善康生物科技有限公司 | Crocodile extract composition for preventing and treating hypertension and preparation method thereof |
| CN106177727A (en) * | 2016-08-05 | 2016-12-07 | 青岛市中心血站 | A kind of pharmaceutical composition the most smooth for vein haemospasia |
| CN106307544A (en) * | 2016-08-24 | 2017-01-11 | 宁波枫叶杰科生物技术有限公司 | Health care product containing herbal extracts |
| CN106360231A (en) * | 2016-08-26 | 2017-02-01 | 桂林丰润莱生物科技股份有限公司 | Solid beverage for nourishing and protecting heart and preparation method thereof |
| CN106334177A (en) * | 2016-10-26 | 2017-01-18 | 鄢庆敏 | Traditional Chinese medicine for treating consumptive disease |
| CN106491835A (en) * | 2016-12-12 | 2017-03-15 | 布伟年 | A kind of anti-senile preparation, its preparation method and application |
| CN106942422A (en) * | 2017-05-15 | 2017-07-14 | 北京喜盛源科技发展有限公司 | A kind of three high drop tea |
| CN107595459A (en) * | 2017-11-02 | 2018-01-19 | 赵书学 | Temporomandibular joint recovery device |
| CN108450729A (en) * | 2018-04-10 | 2018-08-28 | 中南林业科技大学 | A kind of gold ginseng fruit solid beverage and preparation method thereof |
| CN110624091B (en) * | 2019-10-25 | 2021-12-14 | 李玉保 | Ginkgo leaf compound polyphenol capsule with lipid-lowering and thrombolytic effects and preparation method thereof |
| CN110973628A (en) * | 2019-11-29 | 2020-04-10 | 江苏巨托生物科技有限公司 | Alliin food additive and preparation method thereof |
| CN111110773A (en) * | 2020-01-19 | 2020-05-08 | 韩褆 | Microbial fermentation traditional Chinese medicine granule powder for improving immunity and preparation method thereof |
| CN112641884B (en) * | 2020-12-31 | 2021-11-05 | 西安医学院 | Composition for repairing gastric mucosa and improving gastric motility and preparation method thereof |
| CN112891436A (en) * | 2021-02-01 | 2021-06-04 | 缪庆能 | Preparation for promoting circulation in organism and preparation method thereof |
| CN112807333A (en) * | 2021-02-04 | 2021-05-18 | 江西建昌帮食疗科技有限公司 | Composition for enhancing memory and preparation method thereof |
| CN115177658B (en) * | 2021-04-07 | 2024-04-26 | 深圳奥萨制药有限公司 | Composition for reducing blood sugar |
| CN116966222B (en) * | 2023-07-07 | 2024-07-09 | 哈尔滨珍宝制药有限公司 | Traditional Chinese medicine composition for treating liver fibrosis as well as preparation and application thereof |
-
2002
- 2002-07-30 CN CN 02133547 patent/CN1211107C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1390594A (en) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1211107C (en) | Mixture for improving blood circulation | |
| CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1698713A (en) | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof | |
| CN1132615C (en) | Health-care product with function of regulating blood sugar and its preparation method | |
| CN1814216A (en) | Chinese medicine composition for diminishing speckle and pox | |
| CN1246011C (en) | Multi-function health care food and application thereof | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1562337A (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1166402C (en) | Composite Chinese medicine with health care function | |
| CN1679901A (en) | Compound preparation of Jianganling for liver and its making method | |
| CN1480208A (en) | Combination of medication for reducing poison and synergic action in radiotherapy or chemotherapy as well as its preparing method | |
| CN1314418C (en) | Medicine for clearing away lung-heat, eliminating phaegn, reliveing cough and asthma and its preparing method | |
| CN100337665C (en) | Oral medicine for treating diabetes | |
| CN1562144A (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN1634496A (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1253170C (en) | Chinese medicine preparation for treating hepatitis and its preparing and detecting method | |
| CN1730083A (en) | Yuanhe tablet and process for preparing the same | |
| CN1634302A (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1686273A (en) | Theory and medicine for treating high blood fat, fatty liver, liver fibrosis and preparation method | |
| CN1698715A (en) | Heat-clearing abortion-preventing Chinese medicine and its preparation method | |
| CN1634587A (en) | Compound preparation for treating urgent and chronic liver diseases and its preparation method | |
| CN1546533A (en) | Hericium erinaceus sulfate proteoglycan, preparation method thereof and pharmaceutical compositions with the same as active component | |
| CN1559493A (en) | Medicine for treating hapatitis | |
| CN1843397A (en) | Pharmaceutical composition for treating liver disease and its preparation and application | |
| CN1853662A (en) | Pearl cosmetic tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050720 Termination date: 20100730 |